Sibeprenlimab-szsi (VOYXACT) slowed estimated glomerular filtration rate decline versus placebo over 24 months in adult patients with primary IgA nephropathy, according to Phase 3 VISIONARY results announced by Otsuka. Otsuka…
My name is Stephen Savage. I'm happy to say I'm a cancer survivor. I was diagnosed in February, 2019 with a form of adenocarcinoma: esophageal cancer of the lower sphincter.…
As reported of The Manila Times, Health Canada has granted priority review to Chiesi Global Rare Diseases’ new drug submission for FILSUVEZ® (birch triterpenes) topical gel, proposed for treating wounds…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
